Who are Flupentixole's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Crushed ticagrelor, morphine,metoclopramide, Quetiapine 600mg, SAMIDORPHAN L-MALATE, Lybalvi, Caplyta, Nuplazid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/flupentixole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Flupentixole — Competitive Intelligence Brief

Flupentixole (Flupentixole) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antipsychotic. Area: Neuroscience.

marketed Antipsychotic Dopamine D2 receptors Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Flupentixole (Flupentixole) — Technical University of Munich. Flupentixole is a dopamine D2 receptor antagonist that reduces psychotic symptoms by blocking dopamine receptors in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Flupentixole TARGET	Flupentixole	Technical University of Munich	marketed	Antipsychotic	Dopamine D2 receptors
Crushed ticagrelor, morphine,metoclopramide	Crushed ticagrelor, morphine,metoclopramide	Collegium Medicum w Bydgoszczy	marketed	Antiplatelet agent + opioid analgesic + antiemetic (combination therapy)	P2Y12 receptor (ticagrelor); mu opioid receptors (morphine); dopamine D2 receptors (metoclopramide)
Quetiapine 600mg	Quetiapine 600mg	AstraZeneca	marketed	atypical antipsychotic	["serotonin 5-HT2A receptors", "dopamine D2 receptors"]
SAMIDORPHAN L-MALATE	SAMIDORPHAN L-MALATE		marketed	Atypical Antipsychotic [EPC]	dopamine and serotonin type 2 (5HT2) receptors, opioid receptors	2021-01-01
Lybalvi	SAMIDORPHAN	Alkermes Inc	marketed	Atypical Antipsychotic [EPC]	Mu-type opioid receptor	2021-01-01
Caplyta	LUMATEPERONE	Intra-Cellular	marketed	Atypical Antipsychotic [EPC]	5-hydroxytryptamine receptor 2A	2019-01-01
Nuplazid	PIMAVANSERIN	Acadia Pharms Inc	marketed	Atypical Antipsychotic	5-hydroxytryptamine receptor 2A	2016-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2031-08-23 — Lybalvi · 11351166 · US
2031-08-23 — Lybalvi · 11241425 · US
2031-08-23 — Lybalvi · 9126977 · US
2031-08-23 — Lybalvi · 10300054 · US
2031-08-23 — Lybalvi · 10716785 · US
2031-08-23 — Lybalvi · 11185541 · US
2031-08-23 — Lybalvi · 9517235 · US
2031-08-30 — Lybalvi · 9119848 · US
2032-02-13 — Lybalvi · 8778960 · US

Sponsor landscape (Antipsychotic class)

Fundación Pública Andaluza Progreso y Salud · 1 drug in this class
Ludwig-Maximilians - University of Munich · 1 drug in this class
Technical University of Munich · 1 drug in this class
University of Utah · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Flupentixole — Competitive Intelligence Brief. https://druglandscape.com/ci/flupentixole. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab